{"schema_version":"secwatch.filing_event.v1","accession":"0001711279-22-000064","form_type":"8-K","ticker":"KRYS","cik":"0001711279","company_name":"Krystal Biotech, Inc.","filed_at":"2022-11-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.831940+00:00","generated_at":"2026-06-21T16:43:35.891917+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Krystal Biotech subsidiary Jeune reports up to 9-month durability for KB301 in PEARL-1 extension","bullets":["Up to nine months durability of effect observed in patients aged 55-76 following high dose KB301.","Mean Subject Satisfaction Score change from baseline ranged from 1.6 to 1.85 points at 7-9 months.","Responder rate 62-70% based on Subject Satisfaction Score ≥1 point change; Investigator Assessments showed clinically meaningful difference in 70-76% of treated cheeks.","Plan to initiate Phase 2 PEARL-2 study in 1H 2023 for fine lines and wrinkles.","All adverse events were injection-site related, transitory, mild or moderate."],"urls":{"canonical":"https://secwatch.observer/filing/0001711279-22-000064","json":"https://secwatch.observer/filing/0001711279-22-000064.json","markdown":"https://secwatch.observer/filing/0001711279-22-000064.md","text":"https://secwatch.observer/filing/0001711279-22-000064.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711279/000171127922000064/0001711279-22-000064-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711279/000171127922000064/krys-20221117.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T16:43:35.891917+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}